Cytokinetics, Incorporated (CYTK)

How it makes money

In fiscal 2025 the company had no product sales at all. Its revenue came entirely from partners: collaboration revenue of $8.7 million and license and milestone revenue of $79.4 million, for total revenue of $88.0 million against $18.5 million in 2024. The jump was driven by two one-off events — $52.4 million recognised on completing a technology transfer to Bayer Consumer Care AG in the second quarter, and $15.0 million of milestones under the Sanofi licence agreement triggered by the MYQORZO approvals in the United States and China. Revenue of this kind is lumpy by nature: it arrives when a contractual event happens, not steadily. Against it the company spent $416.0 million on research and development and reported a net loss of $785.0 million for the year, funded from roughly $1.22 billion of cash and investments at 31 December 2025. From 2026 the model changes shape: product sales of MYQORZO in the US and Europe, partner-booked sales through Sanofi (China, Taiwan) and Bayer (Japan), minus revenue interests owed to Royalty Pharma on aficamten and omecamtiv mecarbil sales.

What protects Cytokinetics is not scale or brand but paperwork and data: patents on its muscle-directed molecules, the regulatory approval of MYQORZO and the decades of clinical evidence behind it. That is real but narrow. Bristol Myers Squibb got to the same market first with Camzyos (mavacamten), other cardiac myosin inhibitors are in development, and the protection has an expiry date built into it — patents run out and generics follow. The company also owes revenue interests to Royalty Pharma on sales of its two lead drugs, which permanently clips part of the economics the moat is supposed to defend.

Hypertrophic cardiomyopathy and heart failure do not wait for the economy: patients are diagnosed and treated regardless of the business cycle, and cardiology drugs are among the least discretionary spending in healthcare. But that defensiveness says little about Cytokinetics' own revenue for now. Through 2025 the money came from contractual milestones, which arrive in jumps and can be absent for a year. From 2026 onward the variable that matters is launch execution — how quickly cardiologists adopt MYQORZO, how payors cover it, and how the market is shared with an incumbent competitor — not GDP.

Key risks

• Everything now rests on one newly approved drug — The company's near-term prospects depend on market acceptance of MYQORZO, approved only in December 2025 and sold only from 2026. It has no commercial track record, and prior to approval the drug had been manufactured only at clinical-trial scale.
• Losses since 1997 and a continuing need for capital — Cytokinetics has run operating losses every year since its inception in 1997 and expects to need substantial additional capital. Convertible notes carry dilution risk, and accumulated tax losses may be limited in their future use.
• No factories of its own, single-source suppliers — The company has no manufacturing capability and relies on contract manufacturers, several of them single sources of supply; key registered starting materials for aficamten are sourced from manufacturers in China.
• Payors decide whether the drug is actually used — Coverage and reimbursement by third-party payors is disclosed as a dependency: without adequate coverage, approval does not translate into sales.
• Competition in the same indication — The company discloses competitive threats from alternative therapies; Bristol Myers Squibb markets Camzyos (mavacamten) as the first-in-class cardiac myosin inhibitor, and competitors generally have greater capital resources.
• The rest of the pipeline can still fail — Clinical trial execution, patient enrolment and regulatory approval are disclosed risks. Omecamtiv mecarbil already received a Complete Response Letter from the FDA and is being re-tested in the Phase 3 COMET-HF trial.
• Dependence on Sanofi and Bayer — Among its financial risks the company lists dependence on its partnerships with Sanofi and Bayer, which carry the drug in China, Taiwan and Japan and are today the source of most of its revenue.
• Patents and their defence — Intellectual property protection and infringement are disclosed risks: the value of the approved drug and of the pipeline depends on patents holding up against challenge.

The 2025 revenue was extremely concentrated, though the company does not publish a percentage figure for it. Of $88.0 million of total revenue, $52.4 million came from a single technology transfer to Bayer Consumer Care AG and $15.0 million from milestones under the Sanofi licence agreement — two counterparties, and two one-off events. There is no base of ordinary customers behind these figures, because there were no product sales in the year. From 2026 the picture changes: direct sales go through pharmaceutical distributors and specialty pharmacies, a channel that in the United States is itself concentrated in a handful of wholesalers.